catalym
Posted by catalym
November 12, 2021
November 12, 2021

CatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002 at SITC Conference

CatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002...

Read More
trophic
Posted by trophic
October 11, 2021
October 11, 2021

CatalYm Presents Updated Tolerability & Preliminary Pharmacodynamics Data from GDF-15 targeting First-in-Human Clinical Trial...

CatalYm Presents Updated Tolerability and Preliminary Pharmacodynamics Data from GDF-15 targeting First-in-Human...

Read More
trophic
Posted by trophic
September 30, 2021
September 30, 2021

CatalYm To Present Update from GDF-15 Targeting First-in-Human I/O Clinical Trial in Plenary Session at AACR-NCI-EORTC Conference...

CatalYm To Present Update from GDF-15 Targeting First-in-Human I/O Clinical Trial in...

Read More
piomat
Posted by piomat
May 20, 2021
May 20, 2021

CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting

CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody...

Read More
piomat
Posted by piomat
May 19, 2021
May 19, 2021

CatalYm Presents at Bioequity Europe May 17-19 2021 – view presentation

CatalYm Presents at Bioequity Europe May 17-19 2021 – view presentation CatalYm-Bioequity-Corp-presentation-May-2021...

Read More
piomat
Posted by piomat
May 4, 2021
May 4, 2021

CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer

CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer Munich,...

Read More
piomat
Posted by piomat
March 1, 2021
March 1, 2021

CatalYm Announces Key Management and Board Changes

CatalYm Announces Key Management and Board Changes Dr. Manfred Ruediger steps down...

Read More
piomat
Posted by piomat
January 28, 2021
January 28, 2021

CatalYm Starts First-in-Human Phase I Clinical Trial with GDF-15 Neutralizing Antibody CTL-002 to Treat Patients with Checkpoint-Inhibitor Refractory Cancer

CatalYm Starts First-in-Human Phase I Clinical Trial with GDF-15 Neutralizing Antibody CTL-002...

Read More
piomat
Posted by piomat
November 10, 2020
November 10, 2020

CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for checkpoint-inhibitor refractory patients

CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for...

Read More
piomat
Posted by piomat
June 18, 2020
June 18, 2020

CatalYm to Present Data on Targeting Novel Checkpoint GDF-15 for Immunotherapy of Cancer at the AACR Annual Meeting 2020

CatalYm to Present Data on Targeting Novel Checkpoint GDF-15 for Immunotherapy of...

Read More